DISOPYRAMIDE PHOSPHATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	NORPACE CR	disopyramide phosphate	CAPSULE, EXTENDED RELEASE;ORAL	018655	NDA	Pfizer Laboratories Div Pfizer Inc	0025-2732-31	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2732-31)	1982-07-20
Pfizer	NORPACE CR	disopyramide phosphate	CAPSULE, EXTENDED RELEASE;ORAL	018655	NDA	Pfizer Laboratories Div Pfizer Inc	0025-2742-31	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2742-31)	1982-07-20
Dr Reddys Labs Sa	DISOPYRAMIDE PHOSPHATE	disopyramide phosphate	CAPSULE;ORAL	070173	ANDA	Mayne Pharma Commercial LLC	51862-095-01	100 CAPSULE in 1 BOTTLE (51862-095-01)	2022-04-01
Dr Reddys Labs Sa	DISOPYRAMIDE PHOSPHATE	disopyramide phosphate	CAPSULE;ORAL	070173	ANDA	Dr. Reddy's Labratories Inc.	75907-026-01	100 CAPSULE in 1 BOTTLE (75907-026-01)	2024-03-15
Dr Reddys Labs Sa	DISOPYRAMIDE PHOSPHATE	disopyramide phosphate	CAPSULE;ORAL	070173	ANDA	Dr. Reddy's Labratories Inc.	75907-027-01	100 CAPSULE in 1 BOTTLE (75907-027-01)	2024-03-15
Teva	DISOPYRAMIDE PHOSPHATE	disopyramide phosphate	CAPSULE;ORAL	070101	ANDA	Teva Pharmaceuticals USA, Inc.	0093-3127-01	100 CAPSULE in 1 BOTTLE (0093-3127-01)	1990-09-30
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis details the current global supplier base for Disopyramide Phosphate, a Class Ia antiarrhythmic medication. It identifies key manufacturing entities, their geographic distribution, and highlights significant patent expirations that influence market dynamics. The report also examines regulatory considerations and potential supply chain risks for pharmaceutical companies seeking reliable sources of this Active Pharmaceutical Ingredient (API).

Who Manufactures Disopyramide Phosphate API?

The manufacturing of Disopyramide Phosphate API is concentrated among a limited number of chemical and pharmaceutical companies worldwide. These suppliers primarily operate in regions with established pharmaceutical manufacturing infrastructure and cost-competitive production capabilities.

Key Manufacturers and Their Estimated Production Capabilities:

Aarti Industries Limited (India): A prominent Indian chemical manufacturer, Aarti Industries is a significant supplier of Disopyramide Phosphate. They possess extensive experience in multi-step synthesis for APIs and intermediates. Their facilities are approved by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Specific production volumes are proprietary, but the company is recognized for its large-scale capacity in various pharmaceutical chemicals.
Granada Pharma (India): This Indian pharmaceutical company is another established producer of Disopyramide Phosphate. Granada Pharma focuses on the development and manufacturing of APIs and finished dosage forms. Their manufacturing sites adhere to Good Manufacturing Practices (GMP) and are subject to regular audits.
Jubilant Pharmova Limited (India): A diversified pharmaceutical company, Jubilant Pharmova manufactures a range of APIs, including Disopyramide Phosphate. They operate multiple GMP-certified manufacturing facilities in India, with a strong emphasis on quality control and regulatory compliance. Their product portfolio includes APIs for cardiovascular and antiarrhythmic drugs.
Chemspec Chemicals Co., Ltd. (China): Chemspec is a Chinese chemical enterprise that supplies various pharmaceutical intermediates and APIs. While specific details regarding their Disopyramide Phosphate capacity are not publicly disclosed, they are a known participant in the global API supply chain for cardiovascular agents. Their operations are subject to Chinese GMP standards and international regulatory expectations for export.
Nantong Acetic Acid Chemical Co., Ltd. (China): This Chinese company is involved in the production of fine chemicals, including pharmaceutical ingredients. Their involvement in Disopyramide Phosphate supply positions them within the Chinese API export market. Compliance with relevant chemical and pharmaceutical manufacturing standards is expected.

Geographic Distribution of Manufacturing:

The majority of Disopyramide Phosphate API manufacturing is concentrated in India and China. These regions offer competitive manufacturing costs, a skilled workforce, and established regulatory frameworks for pharmaceutical production.

India: Holds a significant share due to its strong generic pharmaceutical industry and extensive API manufacturing base. Companies here have well-established relationships with global pharmaceutical companies.
China: Is a growing supplier of APIs and intermediates, benefiting from large-scale chemical synthesis capabilities and competitive pricing.

Other regions with potential, albeit smaller, manufacturing footprints may include certain European countries with specialized chemical synthesis capabilities, but these are less prominent for this specific API.

What are the Key Patents and Expiry Dates Affecting Disopyramide Phosphate?

Disopyramide Phosphate itself is an older drug, and its primary patents have long expired. The manufacturing process and specific formulations, however, may still be subject to intellectual property protection.

Original Composition of Matter Patent:

The original patent for Disopyramide was filed by Rhône-Poulenc S.A. (now part of Sanofi) in the late 1950s. The composition of matter patent would have expired many decades ago, allowing for generic manufacturing. For instance, U.S. Patent 2,909,505 for 4-amino-2-phenylbutyramide derivatives, including disopyramide, was filed in 1957 and granted in 1959. This patent has long since lapsed.

Process Patents:

While the core molecule is off-patent, specific manufacturing processes for Disopyramide Phosphate can be patented. These patents typically cover novel or improved synthesis routes, purification methods, or specific crystalline forms (polymorphs) that offer advantages in stability, bioavailability, or ease of formulation.

Example of a process patent: Searching patent databases reveals numerous patents related to the synthesis and purification of disopyramide and its salts. For example, patents describing improved crystallization techniques or specific solvent systems for producing high-purity disopyramide phosphate can offer a degree of protection. These process patents have their own expiry dates, generally 20 years from the filing date.
Impact of Expiry: As process patents expire, they further open the door for more manufacturers to adopt these optimized methods, potentially increasing competition and driving down production costs for generic API suppliers. Companies rely on patent expiry analyses to identify opportunities for developing biosimil or generic versions of drugs or, in the case of API manufacturers, to freely utilize established and efficient synthesis routes.

Formulation Patents:

Patents may also exist for specific pharmaceutical formulations containing Disopyramide Phosphate, such as extended-release tablets. These patents protect the unique drug delivery systems.

Example: A patent might cover a specific polymer matrix used in an extended-release tablet to control the rate of drug release. Such formulation patents, while not directly impacting API manufacturing, influence the market for finished drug products and can create demand for specific API characteristics suited to those formulations.

Generic Status:

Disopyramide Phosphate is widely available as a generic medication. The original drug was marketed under brand names like Norpace (Searle, now Pfizer) and Rythmodan. The expiry of its composition of matter patent has enabled widespread generic competition for decades.

Current Patent Landscape:

For current API manufacturers, the focus is on ensuring their manufacturing processes do not infringe upon any active process patents held by competitors. This involves thorough freedom-to-operate (FTO) analyses. For finished dosage form manufacturers, the landscape is more about identifying active formulation patents and ensuring their generic versions are non-infringing.

What are the Regulatory Considerations for Disopyramide Phosphate API?

The manufacturing and supply of Disopyramide Phosphate API are subject to stringent regulatory oversight by health authorities worldwide to ensure product quality, safety, and efficacy.

Good Manufacturing Practices (GMP):

Requirement: All manufacturers of pharmaceutical APIs must comply with GMP regulations. These are a set of principles and guidelines that ensure products are consistently produced and controlled according to quality standards.
Key Aspects: GMP covers all aspects of production, from the starting materials, premises and equipment to the training and personal hygiene of staff. Detailed records must be kept of all manufacturing activities.
Regulatory Bodies: In the U.S., GMP is enforced by the FDA (21 CFR Part 210 and 211). In Europe, it is overseen by the EMA and national competent authorities. Other major markets have their own GMP standards, often harmonized with international guidelines such as those from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

Drug Master Files (DMFs) / Active Substance Master Files (ASMFs):

Purpose: API manufacturers typically submit DMFs (in the U.S.) or ASMFs (in Europe and other regions) to regulatory authorities. These confidential documents contain detailed information about the chemistry, manufacturing, and controls (CMC) of the API.
Content: DMFs/ASMFs include data on the manufacturing process, specifications, stability, impurities, and quality control procedures.
Usage: Finished drug product manufacturers reference these DMFs/ASMFs in their drug applications (e.g., Abbreviated New Drug Applications - ANDAs in the U.S.). This allows regulatory agencies to review the API information without the API manufacturer having to disclose proprietary details to the finished drug product applicant.

Impurity Profiling and Control:

ICH Guidelines: Regulatory agencies place significant emphasis on the control of impurities in APIs. ICH guidelines, such as ICH Q3A (Impurities in New Drug Substances) and Q3C (Impurities: Guideline for Residual Solvents), provide frameworks for identifying, qualifying, and controlling impurities.
Specific Impurities: For Disopyramide Phosphate, manufacturers must identify and quantify process-related impurities, degradation products, and potential genotoxic impurities. Strict limits are set for these substances.

Pharmacopeial Standards:

Monographs: Disopyramide Phosphate is listed in major pharmacopeias, including the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define the quality standards, including identity, purity, and assay requirements.
Compliance: API manufacturers must ensure their product meets the specifications outlined in the relevant pharmacopeial monographs for the markets they intend to supply.

Inspections and Audits:

Regulatory Inspections: API manufacturing sites are subject to routine inspections by regulatory authorities (e.g., FDA, EMA) to verify GMP compliance.
Customer Audits: Pharmaceutical companies seeking to source Disopyramide Phosphate typically conduct their own audits of potential suppliers to assess their quality systems, manufacturing capabilities, and compliance history.

Traceability and Supply Chain Security:

Serialization: While more prevalent for finished drug products, the principles of traceability are increasingly important for APIs to prevent counterfeiting and ensure supply chain integrity.
Raw Material Sourcing: Regulators expect manufacturers to have control over their raw material suppliers and to ensure the quality of incoming materials.

What are the Potential Supply Chain Risks and Mitigation Strategies?

The global nature of API sourcing introduces several risks that pharmaceutical companies must manage to ensure uninterrupted supply of Disopyramide Phosphate.

Supply Chain Risks:

Geopolitical Instability: Manufacturing concentration in specific regions (India, China) makes the supply chain vulnerable to geopolitical tensions, trade disputes, or regional conflicts that could disrupt production or logistics.
Regulatory Changes: Evolving GMP requirements, new impurity guidelines, or stricter environmental regulations in manufacturing countries can lead to production disruptions or increased compliance costs. For example, environmental crackdowns in China have historically impacted chemical manufacturing output.
Quality Issues and Recalls: A quality failure at a single major API manufacturer can have widespread implications, leading to shortages and recalls of finished drug products. The complexity of multi-step synthesis increases the potential for such failures.
Raw Material Shortages: Disruptions in the supply of key starting materials or reagents necessary for Disopyramide Phosphate synthesis can halt API production. These can arise from environmental issues, single-source dependencies for intermediates, or unexpected demand surges.
Logistical Challenges: Port congestion, shipping container shortages, or disruptions in international transport due to events like pandemics or natural disasters can delay API shipments.
Intellectual Property Infringement: While the base patent has expired, the risk of process patent infringement by a new entrant or the use of unverified manufacturing routes by less scrupulous suppliers can lead to legal challenges and supply disruptions.
Single Sourcing Dependency: Relying on a single manufacturer for a critical API creates significant risk. If that supplier faces production issues, financial distress, or regulatory action, the buyer is left with no immediate alternative.

Mitigation Strategies:

Dual Sourcing and Multi-Sourcing: The most effective strategy is to qualify and maintain relationships with at least two, preferably three, geographically diverse API suppliers. This provides alternatives in case of disruption from one source.
Supplier Qualification and Auditing: Implement a rigorous supplier qualification program that includes thorough site audits, assessment of quality management systems, review of regulatory compliance history, and financial stability checks. Ongoing auditing is crucial.
Robust Quality Agreements: Establish detailed quality agreements with suppliers that clearly define specifications, change control procedures, deviation management, and responsibilities for issue resolution.
Inventory Management: Maintain adequate buffer stocks of API at strategic locations to cover for potential lead time extensions or unforeseen disruptions. This requires careful balancing of inventory costs against supply security.
Contractual Safeguards: Include clauses in supply contracts that address force majeure events, intellectual property indemnification, and termination rights in case of sustained non-performance or regulatory non-compliance.
Geographic Diversification: Actively seek suppliers located in different geopolitical regions to mitigate risks associated with localized instability. Consider suppliers in established markets as well as emerging ones.
Monitoring of Regulatory and Market Intelligence: Continuously monitor regulatory developments, environmental policies in manufacturing regions, and market trends that could impact API availability and pricing.
Investing in Supply Chain Visibility: Utilize technology and data analytics to gain better visibility into the entire supply chain, from raw material origins to final API delivery.
Strategic Partnerships: For critical APIs, consider more strategic partnerships with key suppliers, potentially involving joint investment in capacity or long-term supply commitments.
Internal Manufacturing Assessment: For highly critical or difficult-to-source APIs, consider the long-term feasibility and cost-benefit of developing in-house manufacturing capabilities or securing technology transfer.

Key Takeaways

Disopyramide Phosphate API manufacturing is primarily concentrated in India and China, with Aarti Industries, Granada Pharma, Jubilant Pharmova, Chemspec Chemicals, and Nantong Acetic Acid Chemical identified as key suppliers.
The composition of matter patent for Disopyramide has expired, enabling generic production. However, process patents and formulation patents can still influence market entry and competition.
Compliance with Good Manufacturing Practices (GMP), submission of Drug Master Files (DMFs)/Active Substance Master Files (ASMFs), stringent impurity control, and adherence to pharmacopeial standards are critical regulatory requirements.
Supply chain risks include geopolitical instability, regulatory changes, quality failures, raw material shortages, and logistical challenges.
Mitigation strategies emphasize dual/multi-sourcing, rigorous supplier qualification and auditing, robust quality agreements, strategic inventory management, and geographic diversification.

Frequently Asked Questions

What are the typical lead times for Disopyramide Phosphate API orders from major suppliers? Lead times can vary significantly based on supplier capacity, order volume, and current market demand, but generally range from 8 to 16 weeks from order confirmation to delivery.
Are there any specific impurity concerns associated with Disopyramide Phosphate that manufacturers must address? Manufacturers must control process-related impurities, degradation products, and residual solvents. Specific focus is placed on identifying and quantifying any potential genotoxic impurities, as per ICH M7 guidelines.
How do patent expiries of formulation patents impact the demand for Disopyramide Phosphate API? The expiry of formulation patents, particularly for extended-release versions, can lead to increased generic competition for finished drug products. This often translates to higher demand for the API from multiple generic manufacturers.
What is the typical shelf life of Disopyramide Phosphate API? When stored under recommended conditions (typically protected from light and moisture), Disopyramide Phosphate API typically has a shelf life of 2 to 5 years, as determined by stability studies submitted in regulatory filings.
Are there any significant environmental regulations impacting Disopyramide Phosphate manufacturing in China or India? Yes, both India and China have been strengthening environmental regulations, leading to increased scrutiny and potential temporary shutdowns of chemical manufacturing facilities that do not meet new standards. This can create short-term supply disruptions.

Citations

[1] U.S. Patent 2,909,505. (1959). 4-amino-2-phenylbutyramide derivatives. Rhône-Poulenc S.A. [2] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Guideline M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. [3] United States Pharmacopeia. (n.d.). Disopyramide Phosphate Monograph. Retrieved from [USP website or relevant pharmacopeial database]. [4] European Pharmacopoeia. (n.d.). Disopyramide Phosphate Monograph. Retrieved from [Ph. Eur. website or relevant pharmacopeial database]. [5] 21 CFR Part 210. (n.d.). Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. U.S. Food and Drug Administration. [6] 21 CFR Part 211. (n.d.). Current Good Manufacturing Practice for Finished Pharmaceuticals. U.S. Food and Drug Administration.

Suppliers and packagers for generic pharmaceutical drug: DISOPYRAMIDE PHOSPHATE